Namikawa Hiroki, Oinuma Ken-Ichi, Kaneko Yukihiro, Kakeya Hiroshi, Shuto Taichi
Department of Medical Education and General Practice, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Department of Bacteriology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Emerg Microbes Infect. 2025 Dec;14(1):2438657. doi: 10.1080/22221751.2024.2438657. Epub 2024 Dec 16.
Antimicrobial resistance has recently increased due to emerging carbapenem-resistant and extended-spectrum β-lactamase (ESBL)-producing strains of , especially among hypermucoviscous (hmKp) strains. To evaluate the prevalence of ESBL-producing and carbapenem-resistant strains in hmKp and non-hmKp clinical isolates through a systematic review and meta-analysis. We searched PubMed, Scopus, and Cochrane Library databases from January 2000 to June 2023. Clinical and in vivo/in vitro studies involving confirmed clinical isolates differentiated into hmKP and non-hmKP strains based on string test results. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated based on the number of individuals in each target group. Forest plots were used to visualize the effect sizes and 95% CIs of individual studies estimated using the inverse variance and DerSimonian - Laird methods with fixed - and random-effects models, respectively. Heterogeneity was assessed using Cochran's Q test ( ≥ 50%). Fifteen studies comprising 2049 clinical isolates of met the inclusion criteria. Meta-analysis revealed that hmKp strains were associated with a significantly lower prevalence of ESBL-producing strains (pooled OR: 0.26, 95% CI: 0.11-0.63, = 0.003) and a slightly lower prevalence of carbapenem-resistant strains than non-hmKp strains (pooled OR: 0.63, 95% CI: 0.40-0.97, = 0.038). hmKp strains exhibited lower and slightly lower prevalence of ESBL production and carbapenem resistance, respectively, than non-hmKp strains. However, given the rising prevalence of ESBL-producing and carbapenem-resistant hmKp strains, patients infected by string-test-positive must be managed prudently, considering the potential for highly resistant strains.
由于出现了对碳青霉烯类耐药以及产超广谱β-内酰胺酶(ESBL)的菌株,尤其是在高黏液性肺炎克雷伯菌(hmKp)菌株中,抗菌药物耐药性最近有所增加。通过系统评价和荟萃分析来评估产ESBL和耐碳青霉烯类菌株在hmKp和非hmKp临床分离株中的流行情况。我们检索了2000年1月至2023年6月的PubMed、Scopus和Cochrane图书馆数据库。纳入基于悬滴试验结果分为hmKP和非hmKP菌株的确诊肺炎克雷伯菌临床分离株的临床及体内/体外研究。根据每个目标组中的个体数量计算比值比(OR)和95%置信区间(CI)。森林图用于直观展示分别使用固定效应模型和随机效应模型通过逆方差法和DerSimonian-Laird法估计的各研究的效应大小和95%CI。使用Cochrane's Q检验评估异质性(P≥50%)。15项研究共纳入2049株肺炎克雷伯菌临床分离株,符合纳入标准。荟萃分析显示,hmKp菌株中产ESBL菌株的流行率显著低于非hmKp菌株(合并OR:0.26,95%CI:0.11 - 0.63,P = 0.003),耐碳青霉烯类菌株的流行率略低于非hmKp菌株(合并OR:0.63,95%CI:0.40 - 0.97,P = 0.038)。hmKp菌株产ESBL和耐碳青霉烯类的流行率分别低于和略低于非hmKp菌株。然而,鉴于产ESBL和耐碳青霉烯类hmKp菌株的流行率不断上升,对于悬滴试验阳性的肺炎克雷伯菌感染患者,鉴于可能存在高耐药菌株,必须谨慎处理。